Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for 2024, confirming the accuracy and completeness of the financial information. The company’s board of directors, including executive and independent non-executive members, approved the report during a recent meeting. Investors should note that the report complies with PRC Accounting Standards and Hong Kong’s listing rules, reflecting Hepalink’s commitment to transparency.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.